Quotient Sciences Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quotient Sciences Limited - overview
Established
1990
Location
Nottingham, England, UK
Primary Industry
Pharmaceuticals
About
Quotient Sciences Limited, based in the UK, is a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on accelerating drug development through integrated services and advanced technologies. Quotient Sciences Limited specializes in CRDMO services that expedite drug development. Established in 1990 and headquartered in Nottingham, UK, the company has undergone strategic transitions, including a notable acquisition in July 2019 when Permira acquired a majority stake from GHO Capital. The current CEO is Thierry Van Nieuwenhove.
Quotient Sciences has successfully raised a total of GBP 165. 00 mn through its latest funding round, a Secondary Buyout, which occurred on July 18, 2019. The company has completed three investment deals to date. Quotient Sciences offers a wide range of integrated CRDMO services designed to streamline drug development.
Key offerings include formulation development, clinical trial manufacturing, and commercial drug product manufacturing, all enhanced by their proprietary Translational Pharmaceutics® platform. This unique platform facilitates real-time integration of clinical activities with cGMP manufacturing, supporting pharmaceutical and biotechnology companies in various therapeutic areas such as oncology, rare diseases, and neurology across North America, Europe, and Asia. For the most recent fiscal year ending in 2023, Quotient Sciences reported a revenue of GBP 92,387,062. 40 and an EBITDA of GBP 18,549,560.
70. Revenue is primarily generated through B2B partnerships and contractual agreements with clients for their CRDMO services, structured around fee-for-service models and milestone payments tied to project progress. Quotient Sciences is focused on enhancing its market presence and expanding its service offerings. While specific new products have not been detailed for imminent release, the company aims to leverage recent funding from the GBP 165.
00 mn Secondary Buyout to bolster its capabilities. The company may pursue expansion into additional geographic markets, although specific regions and timelines have not been disclosed. The acquisition by Permira is expected to support these strategic growth initiatives.
Current Investors
Permira
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.quotientsciences.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Quotient Sciences Limited - timeline of key events
Quotient Sciences Limited - financials
| Fiscal Year Ended | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | 8,084,000 | 31,661,000 | 38,509,000 | 41,126,000 | 43,379,000 | 56,622,000 | 64,218,000 | 44,763,000 | 70,573,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | 291.7% | 21.6% | 6.8% | 5.5% | 30.5% | 13.4% | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | (8,022,000) | 8,542,000 | 13,452,000 | 10,820,000 | 12,571,000 | 17,505,000 | 6,572,000 | 6,720,000 | 19,805,000 | - | - | - |
| Operating Income (USD) | - | - | - | - | (8,591,000) | 6,653,000 | 11,321,000 | 8,356,000 | 9,894,000 | 14,659,000 | 2,605,000 | 3,687,000 | 15,925,000 | - | - | - |
| Operating Margin | - | - | - | - | (106.3%) | 21.0% | 29.4% | 20.3% | 22.8% | 25.9% | 4.1% | 8.2% | 22.6% | - | - | - |
| % EBITDA Margin | - | - | - | - | (99.2%) | 27.0% | 34.9% | 26.3% | 29.0% | 30.9% | 10.2% | 15.0% | 28.1% | - | - | - |
| NET Income (USD) | 4,000 | 4,000 | 4,000 | 5,000 | (7,968,000) | 3,283,000 | 39,823,000 | 8,606,000 | 7,170,000 | 11,754,000 | 991,000 | 2,107,000 | 13,385,000 | - | - | - |
| % Net Margin | - | - | - | - | (98.6%) | 10.4% | 103.4% | 20.9% | 16.5% | 20.8% | 1.5% | 4.7% | 19.0% | - | - | - |
Quotient Sciences Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Arc Trinova Ltd. | - | ||||||||
| Recapitalisation | Completed | Quotient Sciences Limited | - | ||||||||
| Add-on | Completed | Pharmaterials Ltd | - | ||||||||
| Add-on | Completed | QS Pharma, LLC | - | ||||||||
| Add-on | Completed | SeaView Research | - |
Displaying 1 - 5 of 7
Quotient Sciences Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.